Terms: = Bone cancer AND uPA AND Prognosis
18 results:
1. Prognostic significance of the urokinase plasminogen activator system in tissue and serum of dogs with appendicular osteosarcoma.
Matsuyama A; Wood GA; Speare R; Schott CR; Mutsaers AJ
PLoS One; 2022; 17(9):e0273811. PubMed ID: 36174075
[TBL] [Abstract] [Full Text] [Related]
2. HO-1 Interactors Involved in the Colonization of the bone Niche: Role of ANXA2 in Prostate cancer Progression.
Anselmino N; Bizzotto J; Sanchis P; Lage-Vickers S; Ortiz E; Valacco P; Paez A; Labanca E; Meiss R; Navone N; Cotignola J; Vazquez E; Gueron G
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32197509
[TBL] [Abstract] [Full Text] [Related]
3. Impact of upa/PAI-1 and disseminated cytokeratin-positive cells in breast cancer.
Märkl B; Kazik M; Harbeck N; Jakubowicz E; Hoffmann R; Jung T; Steinfeld D; Schenkirsch G; Schlimok G; Oruzio D
BMC Cancer; 2019 Jul; 19(1):692. PubMed ID: 31307406
[TBL] [Abstract] [Full Text] [Related]
4. u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.
Ciavarella S; Laurenzana A; De Summa S; Pilato B; Chillà A; Lacalamita R; Minoia C; Margheri F; Iacobazzi A; Rana A; Merchionne F; Fibbi G; Del Rosso M; Guarini A; Tommasi S; Serratì S
BMC Cancer; 2017 Mar; 17(1):215. PubMed ID: 28340565
[TBL] [Abstract] [Full Text] [Related]
5. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, upa.
Sgier D; Zuberbuehler K; Pfaffen S; Neri D
Protein Eng Des Sel; 2010 Apr; 23(4):261-9. PubMed ID: 20086040
[TBL] [Abstract] [Full Text] [Related]
6. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract] [Full Text] [Related]
7. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract] [Full Text] [Related]
8. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
[TBL] [Abstract] [Full Text] [Related]
9. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract] [Full Text] [Related]
10. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic and predictive factors revisited.
Hayes DF
Breast; 2005 Dec; 14(6):493-9. PubMed ID: 16239111
[TBL] [Abstract] [Full Text] [Related]
12. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma.
Naka T; Boltze C; Kuester D; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Am J Clin Pathol; 2004 Dec; 122(6):926-30. PubMed ID: 15539385
[TBL] [Abstract] [Full Text] [Related]
13. Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.
Roggel F; Hocke S; Lindemann K; Sinz S; Welk A; Bosl M; Pabst M; Nusser N; Braun S; Schmitt M; Harbeck N
Recent Results Cancer Res; 2003; 162():89-100. PubMed ID: 12790324
[TBL] [Abstract] [Full Text] [Related]
14. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
[TBL] [Abstract] [Full Text] [Related]
15. A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications.
Noack F; Schmitt M; Bauer J; Helmecke D; Krüger W; Thorban S; Sandherr M; Kuhn W; Graeff H; Harbeck N
Int J Biol Markers; 2000; 15(1):100-4. PubMed ID: 10763150
[TBL] [Abstract] [Full Text] [Related]
16. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.
Solomayer EF; Diel IJ; Wallwiener D; Bode S; Meyberg G; Sillem M; Gollan C; Kramer MD; Krainick U; Bastert G
Br J Cancer; 1997; 76(6):812-8. PubMed ID: 9310251
[TBL] [Abstract] [Full Text] [Related]
18. Individual development and upa-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer.
Heiss MM; Allgayer H; Gruetzner KU; Funke I; Babic R; Jauch KW; Schildberg FW
Nat Med; 1995 Oct; 1(10):1035-9. PubMed ID: 7489359
[TBL] [Abstract] [Full Text] [Related]
